Basaglar Injection, Solution
NDC Package 0002-7715-63
Package Information
Basaglar (insulin glargine) injection is bASAGLAR® is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. This formulation utilizes a injection, solution delivery system. Marketed by Eli Lilly And Company, this product is identified by NDC 0002-7715 and is authorized under FDA application BLA205692.
Identification & Billing
- RxCUI: 1736863 - Basaglar KwikPen 100 UNT/ML in 3 ML Pen Injector
- RxCUI: 1736863 - 3 ML insulin glargine 100 UNT/ML Pen Injector [Basaglar]
- RxCUI: 1736863 - 3 ML Basaglar 100 UNT/ML Pen Injector
- RxCUI: 1736863 - Basaglar 300 UNT per 3 ML Pen Injector
- RxCUI: 2268064 - insulin glargine 100 UNT/ML in 3 ML Pen Injector with Sensor
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0002 - Eli Lilly And Company
- 0002-7715 - Basaglar
- 0002-7715-63 - 1 SYRINGE in 1 CARTON / 3 mL in 1 SYRINGE
- 0002-7715 - Basaglar
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0002-7715). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0002-7715-63 identifies a specific commercial package of 1 syringe in 1 carton / 3 ml in 1 syringe of Basaglar Kwikpen, a human prescription drug labeled by Eli Lilly And Company. This injection, solution is formulated for subcutaneous use and contains insulin glargine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Eli Lilly And Company on December 16, 2015. The current certification is valid through December 31, 2027.
How is this Eli Lilly And Company product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00002771563. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.
